Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.23.1
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2023
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the three months ending March 31, 2023 and 2022:

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 

​

    

2023

    

2022

Revenue

​

​

​

​

​

​

Qbrexza®

​

$

4,094

​

$

7,376

Accutane®

​

​

4,648

​

​

4,907

Amzeeq®

​

​

1,193

​

​

3,466

Targadox®

​

​

793

​

​

2,634

Ximino®

​

​

612

​

​

967

Zilxi®

​

​

314

​

​

741

Exelderm®

​

​

511

​

​

704

Other branded revenue

​

​

—

​

​

1

Collaboration revenue

​

​

181

​

​

577

Revenue – related party

​

 

35

​

 

52

Other revenue

​

​

48

​

 

2,500

Net revenue

​

$

12,429

​

$

23,925

​